The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

PSA 2013 Conference

Rebooting Growth: Maximizing the Value of Scientific and Business Model Innovation

In the first decade of this century, industry has adopted more effective and efficient ways of managing R&D, but will those changes be sustainable now that the urgency of the patent cliff is behind it? A rising class of stronger, bigger biotechs has lessons for the rest of the industry on the kinds of innovation acceptable to the market. Are these the right models for this new era? At this year’s PSA: The Pharmaceutical Strategy Conference, we will explore how various players in the biopharmaceutical ecosystem can gain the most value from scientific and business model innovation.

Industry still grapples with existential questions about the most effective approaches to developing meaningful new drugs; how it should collectively fund and reward their discovery and development; which therapies are ultimately worth paying a premium for, and how that worth should be measured. We’ll hear from R&D and business development leaders about changing corporate priorities and strategies, and plans for building businesses in emerging markets that can help resuscitate faltering businesses at home. We’ll also examine what large investors want from large pharma, and at the other end of the value chain, what venture capitalists and entrepreneurs learned from the bloodbath of the past few years.

Pharma now faces market access and pricing challenges that are more insidious, but just as threatening as the familiar R&D and patent cliff issues it has grappled with for years. With the U.S. now fully immersed in implementing health care reform, and austerity abroad, biopharma’s core customer bases face challenges of their own. New information technologies and resource constraints up-end traditional approaches to working with various constituents. Pharma’s responses to these changes continue to evolve. With near-term top- and bottom-line pressures easing, and the broad outline of regulation and policy clearer, biopharma leaders can grow bolder – or more complacent. As industry drives growth in new territories, in new therapeutic spaces, and by forging new kinds of relationships across the changing ecosystem, it may now have its greatest opportunity for transformation ahead of it.

Why do so many pharma companies send their leadership teams to PSA?

PSA offers case studies about today's top biopharma issues from CEOs, Senior R&D and Senior Business Development executives. Not only will they share lessons learned, and practical advice for sealing a deal, but these key opinion leaders will debate the issues that are top of mind -- from enhancing R&D productivity to doing more with less in Business Development. In addition, attendees will also have the chance to:

  • Meet potential partners and network in a relaxed setting.
  • Understand externalization models and see how a company's approach meshes with potential partners.
  • Benchmark the firm's dealmaking strategy against its competitors.
  • Understand the specifics driving biopharma dealmaking to better calibrate ongoing negotiations.
  • View Top 10 reasons to attend Pharmaceutical Strategy Conference.

PSA is the only meeting to gather in one place the industry's top thinkers to explain solutions to the fundamental challenges facing biotech and pharma. In a limited period of time, it will equip dealmakers like you with the insights, information and practical advice you need to strike successful deals. This program will sell out so register early. Space is limited, so register today!

At this year's event you'll hear from and network with senior industry executives about biopharma's most pressing strategic issues. Panel topics include:

  • Innovative approaches to market access.
  • Breakthroughs in business development.
  • Biotech models that create value.
  • What leading investors want from biopharma companies?
  • Balancing austerity and innovation in R&D
  • BD in China: Why it's the right time to partner with domestic biopharma.
  • Matchmaking and integration in the new world of diagnostics M&A.
  • Bringing brand sensibility to biosimilar strategies.

Benchmark your corporate strategies against the best and the brightest.

The BIGGEST Names Send their Leadership Teams to PSA. And the hotel always sells out. Unprecedented networking.

  • Abbott
  • Allergan Inc.
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co.
  • Eli Lilly & Company
  • Genentech
  • Genzyme
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Hoffmann-La Roche
  • Merck and Company
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi
  • UCB Pharma SA

Attend the ONLY strategic-level conference that delivers 100% case studies by the most important people in the business.